Drugs / BBV87
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04603131 | Apr 2017 → Jan 2018 | chikungunya | Bharat Biotech International Limited | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT07555392 | Apr → Sep 2026 overdue | chikungunya | Bharat Biotech International Limited | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04566484 | Aug 2021 → Jul 2022 | chikungunya | International Vaccine Institute | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BBV87 | “This is an open label phase I study for assessing the safety, tolerance and immunogenicity of 3 escalated doses of the test vaccine, BBV87.” NCT04603131 ↗ |
| Known as | BBV87 Chikungunya vaccine | “BBV87 Chikungunya vaccine is a whole virus inactivated vaccine formulated with 0.25 mg aluminum (as aluminum hydroxide) per single human dose.” NCT04566484 ↗ |
| Modality | Vaccine | “inactivated BBV87 chikungunya vaccine” NCT04566484 ↗ |
| Route | Intramuscular | “BBV87 vaccine will be given to participants intramuscularly in the deltoid region of the upper arm.” NCT04566484 ↗ |